Univariate analysis of pre-treatment clinical, circulating and imaging biomarkers for their association with progression free survival (PFS) indicated that PS, LDH, VEGF-A, VEGF-R2, CK18, total tumor volume, IAUC, Ktrans, WTV, ETV, and EF were potential prognostic biomarkers. This evidence concerns the gene VEGFA and neoplasm.